Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports.
Carlos Rocha de LossadaCarmen Alba LineroÁlvaro Santos OrtegaMarina Rodríguez Calvo-de-MoraAnil Rahul RachwaniDavide BorroniEmilio AlbaManuel Benavides OrgazVito RomanoPublished in: Arquivos brasileiros de oftalmologia (2021)
The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- phase iii
- chronic kidney disease
- clinical trial
- prognostic factors
- oxidative stress
- type diabetes
- metabolic syndrome
- low dose
- squamous cell carcinoma
- randomized controlled trial
- patient reported outcomes
- depressive symptoms
- stem cells
- radiation therapy
- physical activity
- patient reported
- insulin resistance
- mesenchymal stem cells
- double blind
- smoking cessation
- cell therapy
- bone marrow